Objectives: To explore different ciprofloxacin dosage regimens for the treatment of intensive care unit (ICU) patients with respect to clinical outcome and the development of bacterial resistance for the major Gramnegative pathogens.
Introduction
Ciprofloxacin is a second-generation fluoroquinolone characterized by a rapid concentration-dependent bactericidal activity against most Gram-negative aerobic species and, to a lesser extent, many Gram-positive microorganisms. 1, 2 This antibiotic is widely used for the treatment of a variety of nosocomial infections, especially in intensive care units (ICUs), as it exhibits bactericidal activity against Pseudomonas aeruginosa, which is one of the most common nosocomial pathogens and a major threat to ICU patients. Ciprofloxacin also has good activity against Acinetobacter baumannii. Furthermore, it is well tolerated 3 and is eliminated by various routes (renal, hepatic and possibly secretion across the enteric mucosa), which is a major advantage in critically ill patients who often present to the ICU with multiple organ dysfunction related to severe acute illness.
Despite these advantages, a major issue associated with the use of ciprofloxacin, and fluoroquinolones in general, is the development of bacterial resistance. For P. aeruginosa, an American study performed in ICU patients reported a notable reduction in its susceptibility to ciprofloxacin from 1993 (89%) to 2000 (68%). 4 This reduction was significantly correlated with the increasing use of fluoroquinolones in that country. Another study performed at the Bellevue University Hospital (St-Etienne, France) investigated the impact on bacterial resistance of reducing fluoroquinolone prescriptions in the ICU. 5 A 6 month restriction period led to a significant recovery of P. aeruginosa susceptibility to ciprofloxacin (P,0.01), with a decrease in resistant strains from 71% in the pre-restriction period to 52% in the post-restriction period. It thus appears necessary to promote a reasoned and optimal use of fluoroquinolones in ICU patients that limits the development of bacterial resistance while guaranteeing clinical efficacy.
Many pharmacokinetic-pharmacodynamic (PK-PD) studies 6 -14 have been performed to date to assess the clinical efficacy of ciprofloxacin and its potential for developing bacterial resistance. All these studies are based on the use of PK -PD surrogate indices as defined by Mouton et al. 15 These PK -PD indices take into account bacterial susceptibility through assessment of the MIC and patient exposure through the determination of individual pharmacokinetic parameters such as the AUC 24 (area under the drug serum concentration -time curve over 24 h at steady state) or the C max (maximal drug serum concentration). The C max /MIC ratio, and more particularly the AUC 24 /MIC ratio, have been shown to be the most relevant PK -PD determinants of clinical cure for fluoroquinolones. 9, 10, 12 However, they might not be the most appropriate indices for the prediction of bacterial resistance. A much better predictor of the emergence of resistance seems to be the time spent within the mutant selection window (T MSW ). 16, 17 The mutant selection window corresponds to the concentration range between the MIC for the wild-type (susceptible) bacteria and the mutant prevention concentration (MPC), which is the concentration that blocks the growth of all single-step resistant mutants. Practically, the MPC corresponds to the concentration preventing bacterial growth at a high inoculum (.10 9 ) using agar dilution methodology. Drug serum concentrations varying between the MIC and the MPC are expected to select and allow amplification of a resistant mutant population by killing susceptible pathogens. The existence of a dangerous drug concentration zone conferring survival advantage to the less susceptible organisms was first introduced by Baquero. 18, 19 The name 'mutant selection window' was given subsequently. 19 -22 The mutant selection window concept proved to be relevant for fluoroquinolones based on in vitro and in vivo experiments. 16,23 -26 Despite these findings, the mutant selection window has never been used as a PK -PD index to evaluate fluoroquinolones dosage regimens. Here, we propose to apply this concept to the evaluation of ciprofloxacin in ICU patients in combination with more classical PK -PD indices related to clinical outcome (AUC 24 /MIC ratio). Several dosage regimens of ciprofloxacin were assessed using Monte Carlo simulations (MCSs), including the common dosage regimens of 400 mg twice or three times a day. Evaluation of these regimens was done for each causative Gram-negative pathogen, irrespective of its prevalence, in line with the so-called precautionary principle. The heterogeneity of the ICU patient population was taken into account by developing a population pharmacokinetic model with 102 ICU patients and validating this model with up-to-date model evaluation tools.
Materials and methods

Population pharmacokinetic model used for MCSs
A population pharmacokinetic model was developed in 102 patients admitted to the ICU of the University Hospital of Toulouse-Rangueil, France, between 2003 and 2008. The pharmacokinetic data were obtained from an extension of a previous study 27 by adding 32 patients to the initial cohort (N ¼70) following approval by our Institutional Review Board. The patients' characteristics are summarized in Table 1 . All patients were mechanically ventilated and under infusion therapy during the time they were in the ICU. Creatinine clearance was obtained from serum creatinine using the Cockcroft-Gault equation 28 (CL Cr Cockcroft ) or was directly measured (in 96 patients out of 102) from the creatinine excreted in the urine over 24 h (CL Cr measured ) using the following equation:
where S Cr and U Cr represent the creatinine concentrations in serum and urine (expressed in mmol/L), respectively, and V corresponds to the urinary flow rate (diuresis) measured using the 24 h urine output (expressed in mL/min). The glomerular filtration rate was also assessed through the use of the simplified equation of modification of diet in renal disease (GFR MDRD ). Ciprofloxacin was administered to ICU patients by the intravenous route as a 1 h infusion (or 30 min infusion for patients receiving 200 mg twice a day). Among the 102 patients included in the study, 86 patients received 400 mg twice a day, 9 patients received 400 mg three times a day, 6 patients received 200 mg twice a day, and 1 patient received 600 mg twice a day. The total daily dose of ciprofloxacin ranged from 400 to 1200 mg with a treatment duration ranging from 3 to 21 days (12 days in average). Blood samples were taken from the patients at the end of the infusion and at various times thereafter. In total, 588 quantifiable concentrations were available for the population pharmacokinetic analysis (5.8 concentrations per patient on average). Blood was collected into 5 mL dry tubes and serum concentrations of ciprofloxacin were then measured using a validated reverse-phase HPLC method, described previously. 31 The lower limit of quantification (LLOQ) of this method was 0.05 mg/L and the calibration curve was linear from 0.05 to 50 mg/L. Within-day and between-day imprecision values were ,8.1% and ,8.6%, respectively, with an inaccuracy of 211%-6.0%. During measurement of the patients' samples, imprecision was always ,20% for the calibration curve and the quality control samples (i.e. 0.1, 2.0 and 40 mg/L) tested in each run period.
29,30
The population pharmacokinetic analysis was performed with NONMEM software, version 6.2 (GloboMax, ICON Development Solutions, Ellicott City, MD, USA), using the first-order conditional estimation with interaction (FOCE-I) method. Patients were randomly assigned to two groups for the analysis: one group of 68 patients (2/3 of patients; 384 observations) was used for model building (building dataset), and one group of 34 patients (1/3 of patients; 204 observations) was used for model validation (validation dataset). Only a few concentrations of ciprofloxacin were below the LLOQ value (,2%) and therefore were excluded from the analysis.
First, a basic model without covariates parameterized for clearances and volumes of distribution was developed using the building dataset. Inter-individual variability was assessed assuming a lognormal distribution of individual pharmacokinetic parameters. Interoccasion variability was also assessed, as most patients (84%) were sampled on different occasions (one occasion corresponding to one drug administration, with 3.1 occasions per patient on average). Second, a covariate analysis was carried out. The following covariates were tested in NONMEM, as they were relevant from a physiological or clinical point of view: CL Cr measured , CL Cr Cockcroft , GFR MDRD , body weight, as well as the reason for the ICU admission (polytrauma, postoperative complication, other medical reasons). Other covariates [age, gender, total protein concentration in blood and illness severity (Simplified Acute Physiology Score or SAPS II)] were also investigated, but a preliminary screening of covariates was made using the predictions of individual random effects: only the covariates found to be significant (P, 0.15) after ANOVA, Wilcoxon or Pearson correlation testing were further tested in NONMEM. In NONMEM, the covariate model was built in a stepwise fashion. A forward selection of covariates was made on each pharmacokinetic parameter separately (a P value ,0.05 was retained as significant). The models obtained for each pharmacokinetic parameter separately were then pooled and a backward deletion approach was applied using a stricter criterion (P,0.001). The final covariate model obtained with the building dataset was evaluated using the validation dataset. This evaluation was performed using advanced validation techniques such as visual predictive checks 32 (VPCs) and normalized prediction distribution errors 33 (NPDEs). NPDEs are considered a much better evaluation tool than the commonly used weighted residuals 34 and are assumed to follow an N(0,1) distribution when the model is correct. They were computed using a specific R package developed by Comets et al. 35 and 3000 replicates of the study design (validation dataset). VPCs graphically compare concentrations observed over time in patients with the concentration -time profiles predicted by the model. The observed concentrations were categorized into bins (time intervals were centred on the time with the maximum number of observations) and percentiles (5th, 50th and 95th) of observations were calculated for each bin. It was verified that these percentiles were globally included within the 95% confidence intervals (CIs) derived from the model predictions (1000 replicates of the validation dataset).
PK -PD MCS studies
The MCSs were performed with Oracle Crystal Ball software v.11.2 (Decisioneering, Inc., Denver, CO, USA). The current dosage regimens of ciprofloxacin were investigated, i.e. 200 mg twice or three times a day, 400 mg twice or three times a day and 600 mg twice daily. Other dosage regimens were also assessed without exceeding a dose of 2400 mg/day: 600 mg three times a day, 800 mg once, twice or three times a day, and 1200 mg once daily. Ciprofloxacin was administered as a 1 h infusion, except for the dose of 200 mg (twice or three times a day), where it was given as a 30 min infusion. In all cases, linear kinetics for ciprofloxacin was assumed.
The classical AUC 24 /MIC index was used as a predictor of clinical outcome, while the time spent within the mutant selection window over 24 h (T MSW ) was used as a predictor for the development of bacterial resistance. In order to be consistent with MIC values (which are free drug concentrations), free ciprofloxacin concentrations and free ciprofloxacin AUC 24 s were simulated using the final population pharmacokinetic model developed from total drug concentrations in ICU patients and an unbound fraction (f u ) that was uniformly distributed over [0.6;0.8]. 36 Steady-state AUC 24 values were computed as the daily dose over individual ciprofloxacin clearance. For the calculation of T MSW , ciprofloxacin concentrations were simulated over 24 h with a step of 0.1 h without any residual error. In order to indicate the use of free drug concentrations in the calculation of AUC 24 /MIC and T MSW , we will use the following notations in the article: fAUC 24 /MIC and fT MSW , as done previously by several authors. 37 -40 The target values for these PK-PD indices were taken from the literature: ≥90 h and ≥175 h for fAUC 24 /MIC (equivalent to a total AUC 24 /MIC ≥125 h 6, 41, 42 and ≥250 h, 43 respectively), and ≤20% or ≤30% for fT MSW based on previous work. 16,23 -26 As the pharmacokinetic model included creatinine clearance as a covariate, creatinine clearance values were generated according to a uniform distribution over [30;120] mL/min (knowing that the 80% prediction interval of creatinine clearance for patients in the present study corresponded to [29; 140] mL/min).
Two sets of PK-PD simulations were carried out with each 10000 patients simulated per dosage regimen investigated. In the first set (Trial 1), the whole distribution of the MICs (both susceptible and resistant strains) was used for the simulations to account for the heterogeneity of the bacterial population within each species. MIC distributions were taken from the European Committee on Antimicrobial Susceptibility Testing (EUCAST) web site 44 for each pathogen of interest (A. baumannii, Enterobacter aerogenes, Enterobacter cloacae, Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis and P. aeruginosa). MPC values were computed from MICs using a uniform distribution over [4;6] for the MPC/MIC ratio. For this first set of simulations, an MCS sensitivity analysis was conducted to explore the degree to which various model inputs (MIC distributions, assumptions on MPC/MIC ratio, pharmacokinetic parameters and covariates) impacted on the results. Sensitivity charts were constructed by assessing the contribution of each assumption to the forecast variance (or uncertainty). The contribution to variance was normalized to 100% among all assumptions and was thus expressed in percentage terms. This contribution could be either positive (the higher the assumed value, the higher the forecast value) or negative (the higher the assumed value, the lower the forecast value), depending on the relationship that an assumption has on the forecast. A second set of simulations (Trial 2) was carried out across each MIC value according Khachman et al.
to a geometric progression from 0.002 to 2 mg/L. As in Trial 1, MPC values were computed from MICs using a uniform distribution over [4;6] for the MPC/MIC ratio. For all simulation sets, the percentage of patients reaching the PK-PD targets was calculated for each dosage regimen of ciprofloxacin investigated.
Results
Population pharmacokinetic model for ciprofloxacin
Ciprofloxacin serum concentrations were best described by a two-compartment model with zero-order input (infusion) and first-order elimination. A proportional error model was selected to model residual error. As 1-shrinkage 45 was fairly low (22%), individual goodness-of-fit plots were quite informative, supporting the choice of a two-compartment model. At the end of the model-building process, no significant covariate was found on V1, Q and V2. Only CL Cr Cockcroft remained in the final model as a covariate on CL, as CL ¼ u1×(CL Cr Cockcroft /91. 7) u2 . Inclusion of CL Cr Cockcroft in the model led to a decrease in inter-individual variability from 60% (basic model without covariates) to 50% (final model). Finally, inter-occasion variability was estimated on CL with a value of 21%, which is quite low. Taking into account this inter-occasion variability in the model led to a significant drop in objective function (P,0.001) as well as a reduced residual error (from 25% to 22%). It is noteworthy that there was no deterministic trend with time for the random effects coding for inter-occasion variability, supporting no improvement or alteration of the patient's general status with time. Full variance-covariance matrices were tested in the end for inter-individual and inter-occasion variability, but as this did not lead to any significant decrease in objective function, diagonal variance-covariance matrices were kept. Parameter estimates of this final model are given in Table 2 .
The model was then evaluated using the validation dataset based on VPCs and NPDEs. VPC plots are shown in Figure 1 for the dose of 400 mg twice daily over 24 h (accounting for 74% of patients in our study). Overall, the distribution of observed concentrations in the validation dataset was consistent with the distribution of concentrations predicted by the model. A more global evaluation with respect to covariates and dosage regimens was performed using the NPDEs. Since the (Figure 2) , the model was considered appropriate. Therefore, building and validation datasets were pooled and the model was refined by re-estimating all the parameters on the global dataset. The final parameter estimates are given in Table 2 . Globally these parameter estimates were similar to those obtained with the building dataset. Inter-occasion variability was small (34% on clearance only) and thus was not taken into account for the PK -PD simulations. Table 3 and Table 4 show the target achievement rates (TARs) obtained with the first set of simulations (Trial 1) using the whole MIC distribution for each pathogen of interest. For the fAUC 24 /MIC index accounting for clinical outcome (Table 3) , high TARs (≥78%) were achieved for K. pneumoniae, P. mirabilis, E. cloacae and E. coli with the dosage regimens of 400 mg twice or three times a day, irrespective of the target (≥90 or ≥175 h). In contrast, for the same dosage regimens and the less stringent target (fAUC 24 /MIC ≥90 h), suboptimal TARs were obtained for A. baumannii (52% and 59%), E. aerogenes (56% and 58%) and P. aeruginosa (63% and 70%), respectively. Increasing the daily dose to 2400 mg/day did not enable TARs .66% to be reached for A. baumannii and E. aerogenes.
PK -PD MCSs
Regarding the PK -PD index for the selection of bacterial resistance fT MSW (Table 4) , the target of ≤20% was reached with relatively high TARs with E. aerogenes, E. cloacae, E. coli, K. pneumoniae and P. mirabilis for the common dosage regimens 400  90  52  85  78  82  33  45  87  44  81  69  75  14  21  600  91  54  88  82  84  43  57  89  49  85  75  79  24  36  800  92  56  89  84  86  52  63  90  52  85  78  82  33  46  1200  93  58  91  86  87  59  70  91  55  88  82  85  46  57  1600  93  59  92  87  88  63  74  92  56  89  84  86  53  63  1800  93  60  93  88  88  64  75  92  57  90  85  85  54  65  2400  93  62  94  89  89  66  79  93  58  91  86  86  59  70 ESC, Escherichia coli; EA, Enterobacter aerogenes; EC, Enterobacter cloacae; KP, Klebsiella pneumoniae; PM, Proteus mirabilis; AB, Acinetobacter baumannii; PSA, Pseudomonas aeruginosa. fAUC 24 /MIC represents the area under the free drug concentration -time curve over 24 h in steady-state conditions divided by the MIC. MIC distributions were obtained for each pathogen from the EUCAST web site. 44 Khachman et al.
of 400 mg twice or three times a day. However, for the same dosage regimens and the pathogens P. aeruginosa and A. baumannii, the best TARs achieved for fT MSW ≤20% were ,41%-46%. To achieve .50% of patients for whom the target is reached for P. aeruginosa and A. baumannii, our simulations showed that the daily dose needs to be increased to 1800 or 2400 mg (e.g. 600 or 800 mg three times a day). In that case, the best TARs we might expect for these two pathogens are 58% -61%. An MCS sensitivity analysis was performed for this first set of simulations. Figure 3 shows the sensitivity charts obtained for the dosage regimen of 400 mg twice daily against E. coli, which are globally representative of other dosage regimens and other pathogens. Overall, the sensitivity analysis indicates that the fAUC 24 /MIC ratio is mainly influenced by the shape of the MIC distribution (with absolute contribution values of 68% -96% depending on the pathogen and dosage regimen) and moderately by the ciprofloxacin clearance independent of CL Cr Cockcroft (with absolute contribution values of 3.2% -28%). In contrast, the creatinine clearance calculated with the Cockcroft -Gault equation (CL Cr Cockcroft ) contributed little to the overall variance (range 0.5% -3.6%). fT MSW was also found to be influenced by the shape of the MIC distributions, although to a lesser extent than fAUC 24 /MIC (with absolute contribution values of 0.0% -93%). In addition, the contribution of ciprofloxacin clearance independent from CL Cr Cockcroft was substantial (0.1%-63%), as well as the MPC/MIC ratio (2.6% -87%). As for the fAUC 24 /MIC index, CL Cr Cockcroft did not appear to have a relevant impact on fT MSW (0.0%-8.2%).
The results obtained for the second set of PK -PD simulations (Trial 2) on single-point MIC values (varying from 0.002 to 2 mg/L) are shown in Figure 4 for both fAUC 24 /MIC ≥90 h and fT MSW ≤20% targets. As expected for fAUC 24 /MIC, TARs increased with a lower MIC value and a higher daily dose. A totally different U-shaped curve was observed for fT MSW with high TARs at very low or very high MIC values and low TARs in between. Considering the breakpoint of 1 mg/L 46 for P. aeruginosa given by the Antibiogram Committee of the French Microbiology Society, 46 the simulations predict low TARs for fAUC 24 /MIC ≥90 h with 400 mg of ciprofloxacin twice a day (2.0%) or three times a day (12%), and only a daily dose of 2400 mg allowed a TAR of about 60% to be achieved. For all other pathogens investigated, the Antibiogram Committee of the French Microbiology Society gives an MIC breakpoint of 0.5 mg/L. 46 Considering this value and an fAUC 24 /MIC target of 90 h, the most commonly used dosage regimen of 400 mg twice daily led to only 30% as the TAR and it was necessary to raise the dose to at least 1600 mg/day to achieve a TAR .80%. With respect to the selection of bacterial resistance, all the investigated dosage regimens could result in the possible emergence of bacterial resistance, since more than 91% of patients had their systemic free concentrations of ciprofloxacin within the mutant selection window for .20% of the time with MIC breakpoints of 0.5 and 1 mg/L.
Discussion
The present PK-PD simulation studies were performed in order to assist clinicians in optimising ciprofloxacin dosing regimens in ICU patients. The clinical outcome was evaluated through the use of the AUC 24 /MIC index, while the risk of emergence of bacterial resistance was evaluated through the use of a new index that is the time spent within the mutant selection window (T MSW ). Two MCS trials were performed. The first one used, for each pathogen of interest, the whole distribution of the MICs taken from the EUCAST web site. 44 The second simulation trial was carried out across each MIC value according to a geometric progression from 0.002 to 2 mg/L. While the objective of Trial 1 was to address the case of empirical antibiotherapy 
JAC
(where the MIC of the causative pathogen for a given patient is unknown), the aim of the second set of simulations was to explore the 'worst-case' scenario using MIC breakpoints given by the Antibiogram Committee of the French Microbiology Society. 46 For the calculation of AUC 24 /MIC and T MSW indices, it was first necessary to assess the pharmacokinetics of ciprofloxacin in that specific population of patients as well as the associated interindividual variability. This variability was expected to be high, since ICU patients represent a highly heterogeneous population with various disease conditions and many different co-treatments. Although previous population pharmacokinetic models have been developed in ICU patients, these models were all built on a smaller database (32 -74 patients at the most) and model validation, when performed, only used basic evaluation techniques (e.g. weighted residuals). 27, 47, 48 Proper model evaluation is essential, however, to ensure that the model used for the MCS correctly predicts pharmacokinetic data in the target patient population. The present population pharmacokinetic model was built from a total of 102 ICU patients and was validated using data splitting and more advanced model evaluation tools (VPC and NPDE). 32, 33 Furthermore, in contrast to previous studies, this was the first time inter-occasion variability was assessed. The evaluation of interoccasion variability is important, as it may affect the ability to reach PK-PD targets from one occasion to the other.
The serum concentrations of ciprofloxacin obtained in the 102 ICU patients were best described by a two-compartment model Khachman et al.
with zero-order input and first-order elimination, which is consistent with previous findings. 27, 47 Inter-individual variability was high, especially on ciprofloxacin clearance (60% in the basic model without covariates), and only moderate interoccasion variability on clearance was found (34% in the final model). The covariate analysis did not evidence any significant relationship between ciprofloxacin clearance and the creatinine clearance measured using the 24 h urine output (CL Cr measured ), which is the best estimate of glomerular filtration rate in ICU patients. This suggests that glomerular filtration may not be a major route of elimination for ciprofloxacin in these patients, although urinary recoveries of ciprofloxacin range from 40% to 60% in the literature. 49 Actually the renal clearance of ciprofloxacin was shown to greatly exceed the glomerular filtration rate (indicating tubular secretion) and one-third to one-half of ciprofloxacin clearance is non-renal. 49 Unexpectedly we observed in our analysis a significant relationship between ciprofloxacin clearance and creatinine clearance calculated with the Cockcroft -Gault formula (CL Cr Cockcroft ), showing that CL Cr measured and CL Cr Cockcroft were not equivalent. It is noteworthy that the Cockcroft -Gault equation assumes a normal creatinine production rate based on age, weight and gender and that this formula overestimates creatinine clearance in patients who have abnormally low production rates (due to hepatic failure or a decrease in muscle mass as a result of disease and confinement). The superiority of CL Cr Cockcroft over CL Cr measured for ciprofloxacin clearance and the non-linear nature of the relationship might be explained by the fact that the Cockcroft -Gault equation includes additional information related to body weight, age and gender. In the present study, however, CL Cr Cockcroft only explained a small part of the inter-individual variability, with in the end 50% of unexplained inter-individual variability. This large unexplained variability might be due to variability in the patients' condition, fluid therapy and possibly co-treatments (ICU patients are polymedicated), although drug -drug interactions influencing ciprofloxacin pharmacokinetics have rarely been reported. 50, 51 Hepatic failure might occur in ICU patients as a consequence of decreased perfusion and oxygen delivery to the organ during severe sepsis. In the present case, the potential influence of liver function on ciprofloxacin pharmacokinetics could not be tested due to the large amount of missing data for aspartate aminotransferase (SGOT), alanine aminotransferase (SGPT), alkaline phosphatase and bilirubin. Overall, despite some differences in model parameterization, we find relatively similar pharmacokinetic parameter estimates compared with previous population pharmacokinetic analyses, with relatively similar magnitudes of inter-individual variability. 27, 47 The final population pharmacokinetic model in ICU patients was then used to perform PK -PD MCSs to evaluate several ciprofloxacin dosage regimens with respect to clinical outcome and bacterial resistance. The AUC 24 /MIC and C max /MIC ratios are wellestablished predictors of clinical outcome. 6, 11, 13, 14 However, they have been, and still are, used as predictors of the emergence of bacterial resistance. In the 1990s, another index was proposed for bacterial resistance, which is the T MSW . 19 The relevance of this index for fluoroquinolones was shown experimentally by Firsov and his collaborators, who found a correlation between the percentage of time drug concentrations were within the mutant selection window and the decrease in Staphylococcus aureus susceptibility following exposure to various fluoroquinolones in vitro. 16, 23, 24 In particular, they showed that the susceptibility of S. aureus to gatifloxacin, levofloxacin, moxifloxacin and ciprofloxacin declined when the T MSW was .20% of the dosing interval, regardless of the AUC 24 /MIC ratio, whereas the susceptibility did not change when the T MSW was ,20% of the dosing interval. 16 These results are in line with two in vivo studies performed in rabbits infected with Streptococcus pneumoniae. In these studies, resistant pathogens were 400 mg/day 600 mg/day 800 mg/day 1200 mg/day 1600 mg/day 1800 mg/day 2400 mg/day 800 mg qd 400 mg q12h 800 mg q8h 1200 mg qd 600 mg q12h 400 mg q8h 800 mg q12h 600 mg q8h Figure 4 . Probability of target attainment of fAUC 24 /MIC ≥90 h (left side) and fT MSW ≤20% (right side) at in vitro MIC values varying from 0.002 to 2 mg/L for 10000 PK -PD simulations of different intravenous ciprofloxacin dosage regimens for ICU patients. fAUC 24 /MIC represents the area under the free drug concentration-time curve over 24 h in steady-state conditions divided by the MIC. fT MSW represents the proportion of time (%) spent within the mutant selection window for free drug over 24 h. For doses from 800 to 2400 mg/day, the different areas correspond, respectively, from left to right to: (i) area with maximum efficacy, (ii) area with maximum likelihood of selecting resistance, and (iii) area with minimum efficacy and lower likelihood of selecting resistance. The abbreviations qd, q12h and q8h correspond, respectively, to once, twice and three times a day.
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Based on these findings, two different targets (T MSW ≤20% and T MSW ≤30%) were selected for the present MCS studies. We also extended the mutant selection window concept to Gramnegative organisms as previously reported in one publication for many quinolones including ciprofloxacin. 52 We show with our simulations that there is a priori a high risk of selecting resistance for P. aeruginosa and A. baumannii with the commonly used dosage regimens of 400 mg twice or three times a day. Indeed, ,50% of patients would attain the target of a T MSW ≤20% for these two pathogens. These findings are consistent with the general view that there is low or decreased susceptibility of P. aeruginosa and A. baumannii to fluoroquinolones in hospitals. 53 We also show that increasing the dose to 800 mg three times a day does not lead to a major improvement in the TAR ( 58% -61% at the most). Based on these results, it thus appears necessary to combine ciprofloxacin with another antibiotic when treating P. aeruginosa and A. baumannii or to switch to another antibiotic such as an aminoglycoside. Burgess and Nathisuwan 54 reported that P. aeruginosa isolates exposed to combination therapy developed resistance significantly less often than those exposed to ciprofloxacin monotherapy. In our pharmacokinetic study, it is noteworthy that piperacillin/tazobactam (which are active against P. aeruginosa) were automatically co-administered to ICU patients.
It is currently believed that the problem of bacterial resistance can be systematically addressed by increasing patients' exposure to the antibiotic and thus increasing the dose. 48, 55 When we consider T MSW as an index of the development of resistance, this is not always true. Actually this depends on the values of serum concentrations reached with a given dose relative to MIC and MPC values. If drug serum concentrations are initially lower than the MIC value, increasing the dose may lead to serum concentrations right within the mutant selection window, hence maximizing the likelihood of developing resistance. The use of T MSW as a PK -PD index is in line with general thoughts on antimicrobial dosing strategy that the comparison of different dosing regimens cannot be restricted to the comparison of systemic exposures (AUC) because very different serum concentrationtime profiles may result in the same AUC. 56 For ciprofloxacin, we show that the issue of resistance is mainly due to MIC values ranging between 0.25 and 1 mg/L, for which all dosage regimens led to ciprofloxacin serum concentrations within the mutant selection window for .20% of the time in the majority of the patients in our simulation studies (Trial 2). In contrast, for very low and very high MIC values, ciprofloxacin serum concentrations were mainly outside the mutant selection window, either above the MPC (for low MIC values) or below the MIC (for high MIC values), giving a likely lower risk of resistance, but also lower clinical efficacy. In the present MCS, we assumed that the MPC/MIC ratio followed a uniform distribution over [4;16] even though we are aware that the MPC cannot be accurately predicted from the MIC. 57, 58 This hypothesis was necessary to guarantee an MPC value greater than the MIC value in the simulations. Furthermore, by doing so we covered most of the range of MPC/MIC ratio values published previously. 57 -59 Concerning the clinical outcome, we found that for the current dosage regimen of 400 mg three times a day, the target of fAUC 24 /MIC ≥90 h (equivalent to total AUC 24 /MIC ≥125 h) 6, 41, 42 was achieved in 70% of the patients for P. aeruginosa and 93% of the patients for E. coli. These TARs are higher than in previous MCS studies for the same defined target. 7,8,38,60 -64 However, it should be noted that many of these previous studies used pharmacokinetic data obtained in healthy volunteers, not ICU patients. 7,8,38,60 -63 Since major differences in ciprofloxacin pharmacokinetics have been reported between ICU patients and healthy volunteers (with a two times lower clearance in patients than in healthy volunteers), 27, 47, 65 the TARs produced by these studies are much lower than they should be due to an inaccurate prediction of drug systemic exposure. Unexpectedly, when the appropriate pharmacokinetic information in patients was used, the reported TARs are still lower than the ones found with the present MCSs. 64, 66 For instance, for the same dosage regimen of 400 mg three times a day, Eagye et al. 66 and Kim et al. 64 reported, respectively, 39% and 57% of TARs for P. aeruginosa and 69% and 47% of TARs for E. coli. As the pharmacokinetic data are similar, the differences in TARs can only be imputed to the choice of the target 66 or the choice of the MIC distribution. The sensitivity analysis performed for the present article shows that the main factor influencing the fAUC 24 /MIC forecast is the MIC distribution. Here, we used MIC distributions given by the EUCAST web site 44 for each Gram-negative pathogen of interest. The EUCAST database gathers data from both national and international studies, including resistance surveillance programs such as Meropenem Yearly Susceptibility Test Information Collection (MYSTIC), Alexander. It also includes MIC distributions from previously published articles as well as data collected from the pharmaceutical industry and individual laboratories. The information used to establish the MIC distribution is thus large (with 1181 -27387 isolates per pathogen in our case). Regarding the previous MCS studies, the MIC distributions were taken from the 2007 US MYSTIC Program (global surveillance) 64 or systemic isolates of E. coli and P. aeruginosa collected from medical or surgical wards or ICUs from 40 US hospitals. 66 It is obvious that our findings are only valid for the MIC distributions chosen, and one may wonder how much these distributions are representative of the MIC distribution of the specific population of patients in the ICU. It is possible that there is a selection of more resistant strains in ICUs than in the rest of the hospital services, and further studies will be required to compare results about TARs using MIC distributions established for ICU patients specifically. In any case, all previous MCS studies focused on the current dosage regimens (i.e. 400 mg twice or three times a day) and no other dosage regimens were explored.
Using the whole MIC distribution for each pathogen is in line with empirical antibiotherapy where the MIC of the causative pathogen is unknown. As here, the goal was not to evaluate a single TAR, but to document dose optimization with respect to each causative pathogen; the prevalence of each pathogen was not taken into account. Another approach commonly used for assessment of clinical outcome is the 'worst-case' scenario. In the 'worst-case' scenario, PK -PD surrogate indices are calculated at the MIC corresponding to MIC breakpoints for a given pathogen. The MIC breakpoints from the Antibiogram Committee of the French Microbiology Society are equal to 1 mg/L for P. aeruginosa and 0.5 mg/L for all other pathogens investigated. 46 Considering these breakpoints and the target fAUC 24 /MIC ≥90 h, we show, through the second simulation Khachman et al.
trial (performed on single-point MIC values), that the maximal daily dose of 1200 mg gives a TAR of only 12% for P. aeruginosa and the best TAR we might expect by increasing the daily dose to 2400 mg is 62%. For the other pathogens (MIC of 0.5 mg/L), the daily dose of 1200 mg leads to a TAR of 61%, and much better rates (≥82%) are achieved with a daily dose ≥1600 mg. Considering both MIC breakpoints (0.5 and 1 mg/L), the target fT MSW ≤20% and the dosage regimen of 400 mg three times a day, the TARs vary between 0.32% and 1.3%, and increasing the dose does not result in major improvement. In other terms, based on these breakpoints, there would be problems of resistance for all pathogens investigated with the current dosage regimens, which seems irrelevant. MCSs using the whole MIC distribution for each pathogen give more reasonable results in terms of resistance, which suggests that the breakpoints of antibiograms should be used with caution and should probably be revised.
Conclusion
Our PK -PD MCSs show the weaknesses of the current ciprofloxacin dosage regimens (400 mg twice or three times a day) for the treatment of ICU patients, not in terms of clinical outcome (as in previous studies), but in terms of likelihood of bacterial resistance. Problems of resistance are suggested for P. aeruginosa and A. baumannii, which are usually incriminated in nosocomial infections resistant to ciprofloxacin in ICUs. It should be borne in mind that these simulations are only valid for the MIC distributions taken from EUCAST. Further work should therefore consider local MIC distributions in ICUs and directly evaluate target attainment rates in this subpopulation of patients. In addition, the concept of the mutant selection window and target attainment rates applied to ciprofloxacin in ICU patients need to be validated clinically.
In conclusion, our PK-PD simulations show the need for a reappraisal of the use of ciprofloxacin in ICU patients relative to the issue of bacterial resistance. We therefore reach the same conclusions as previous studies regarding the need to associate another antibiotic in the treatment of P. aeruginosa and A. baumannii (as done in practice) or to switch to another antibiotic (such as aminoglycoside) that would be more efficient against P. aeruginosa and A. baumannii and that would lead to lower rates of resistance.
